preval
chronic
viral
infecti
diseas
human
immunodefici
viru
hiv
hepat
c
viru
hcv
influenza
viru
emerg
reemerg
new
viral
infect
picornavirus
coronavirus
particularli
resist
current
use
antivir
drug
led
increas
demand
new
antivir
strategi
reagent
increas
understand
molecular
mechan
viral
infect
provid
great
potenti
discoveri
new
antivir
agent
target
viral
protein
host
factor
virustarget
antivir
function
directli
indirectli
inhibit
biolog
function
viral
protein
mostli
enzymat
activ
block
viral
replic
machineri
hosttarget
antivir
target
host
protein
involv
viral
life
cycl
regul
function
immun
system
cellular
process
host
cell
review
key
target
consider
develop
antivir
strategi
virus
compris
larg
group
pathogen
respons
caus
sever
infecti
diseas
past
year
antivir
agent
target
viral
protein
host
factor
success
develop
base
inhibitori
mechan
antivir
reagent
divid
two
group
inhibitor
target
virus
ii
inhibitor
target
host
cell
factor
virustarget
antivir
vta
function
directli
dvta
indirectli
indvta
inhibit
biolog
function
viral
protein
mostli
enzymat
activ
block
correct
format
viral
replic
machineri
tabl
hosttarget
antivir
hta
includ
reagent
target
host
protein
involv
viral
life
cycl
figur
regul
function
immun
system
cellular
process
host
cell
increas
knowledg
viral
protein
host
factor
scientif
commun
achiev
great
progress
mechanismbas
antivir
discoveri
chronic
viral
infecti
diseas
understand
emerg
new
viral
diseas
resist
tradit
antivir
review
highlight
recent
achiev
antivir
develop
discuss
variou
strategi
prevent
viru
attach
entri
host
cell
well
strategi
prevent
viru
replic
transcript
within
host
cell
first
step
viral
invas
attach
host
cell
via
interact
function
receptor
envelop
virus
viral
protein
locat
outer
envelop
virion
respons
recognit
receptor
attach
host
cell
hiv
member
retrovirida
famili
typic
envelop
viru
invas
mediat
envelop
protein
arrang
viral
membran
trimer
three
transmembran
three
noncoval
attach
surfac
subunit
figur
recogn
receptor
launch
conform
chang
expos
bind
site
bind
coreceptor
ie
antagonist
block
interact
hiv
receptor
coreceptor
therefor
develop
antihiv
therapeut
attempt
find
specif
inhibitor
block
interact
initi
use
solubl
extracellular
domain
protein
retain
abil
bind
although
preliminari
result
reveal
either
solubl
protein
fusion
protein
show
good
vitro
antihiv
activ
fail
clinic
trial
due
poor
pharmacokinet
featur
eg
halflif
fusion
protein
mice
h
small
molecul
inhibitor
occupi
specif
region
within
pocket
subsequ
develop
block
interact
figur
exampl
found
significantli
reduc
prolifer
good
pharmaceut
characterist
anoth
success
influenza
neuraminidas
na
inhibitor
nai
influenza
na
surfac
glycoprotein
function
two
step
viral
life
cycl
cleav
cell
receptor
sialic
acid
residu
bind
influenza
hemagglutinin
ha
allow
releas
progeni
viru
ii
cleav
sialic
acid
moieti
mucin
bath
airway
epitheli
cell
cobind
receptor
ha
line
structur
na
sever
nai
success
develop
competit
occupi
sialic
acidbind
pocket
na
among
nai
oseltamivir
zanamivir
first
use
clinic
antiflu
therapi
oseltamivir
prodrug
readili
absorb
gastrointestin
tract
convert
hepat
esteras
activ
compound
oseltamivir
carboxyl
zanamivir
poor
oral
bioavail
current
avail
dri
powder
mix
lactos
moreov
laninamivir
peramivir
also
approv
north
asia
recent
laninamivir
excel
vitro
activ
wild
type
well
oseltamivirresist
influenza
virus
current
circul
addit
peramivir
anoth
nai
differ
structur
inhibitor
novel
substitut
result
multipl
bind
interact
activ
site
allow
antivir
activ
nairesist
virus
nonenvelop
virus
picornaviru
picornavirida
famili
human
papillomaviru
hpv
papillomavirida
famili
interact
function
receptor
viral
capsid
protein
picornavirus
typic
nonenvelop
virus
member
includ
enteroviru
human
rhinovirus
hrv
respons
caus
sever
human
infect
diseas
nonenvelop
capsid
picornavirus
icosahedr
structur
compris
copi
viral
structur
protein
adopt
bbarrel
configur
arrang
icosahedr
symmetri
surround
axe
altern
around
axe
although
receptorbind
site
surfac
picornaviru
capsid
conserv
site
use
discov
inhibitor
block
virusreceptor
interact
exampl
canyon
structur
surfac
hrv
capsid
serv
bind
hrv
receptor
solubl
portion
intercellular
adhes
numer
compound
compet
put
hrv
receptor
bind
site
shown
bind
nearbi
hydrophob
pocket
inhibit
viru
attach
receptor
howev
none
compound
clinic
success
date
attach
host
cell
viru
releas
genom
cytoplasm
endocytosi
direct
membran
fusion
viral
entri
one
key
earli
step
viral
life
cycl
figur
entri
inhibitor
success
develop
antivir
therapi
envelop
viru
use
facilit
entri
process
activ
bind
receptor
extracellular
portion
contain
two
heptad
repeat
domain
separ
loop
region
hydrophob
fusion
peptid
fp
n
terminu
fusion
process
fp
insert
host
cell
membran
adopt
triplestrand
coiledcoil
structur
form
metast
prefus
intermedi
subsequ
fold
hydrophob
groov
coiledcoil
form
stabl
sixhelix
bundl
juxtapos
viral
cellular
membran
fusion
figur
fusion
inhibitor
design
block
conform
chang
requir
membran
fusion
peptid
enfuvirtid
peptid
mimic
act
competit
bind
first
clinic
approv
fusion
inhibitor
inhibit
broad
rang
hiv
strain
nanomolar
level
poor
bioavail
drug
plasma
halflif
h
make
clinic
applic
drug
difficult
overcom
pharmacokinet
disadvantag
seri
modifi
peptid
includ
sifuvirtid
gener
stabil
helic
structur
peptid
incorpor
intrahel
salt
bridg
helix
turn
particular
plasma
halflif
sifuvirtid
greater
moreov
chemic
modif
includ
pegyl
glycosyl
also
introduc
improv
pharmacokinet
fusion
inhibitor
altern
subset
bioavail
small
molecul
fusion
inhibitor
develop
target
pocket
trimer
undefin
region
similar
strategi
success
use
mani
virus
use
class
fusion
mechan
includ
influenza
viru
ebola
viru
filovirida
famili
sever
acut
respiratori
syndrom
coronaviru
sarscov
coronavirida
famili
approach
rare
antivir
develop
target
virus
class
iiiii
fusion
mechan
howev
difficulti
product
deliveri
mean
none
small
molecul
fusion
inhibitor
approv
clinic
use
nonenvelop
virus
use
differ
strategi
viru
entri
attach
receptor
nonenvelop
viru
releas
genom
host
cell
conform
shift
capsid
protein
exampl
capsid
harbor
copi
hydrophob
pocket
factor
natur
lipid
sphingosin
base
canyon
capsid
protein
figur
expuls
sphingosin
follow
bind
viru
receptor
trigger
open
capsid
releas
viral
genom
pleconaril
two
exampl
hydrophob
compound
replac
natur
pocket
factor
inhibit
picornavir
uncoat
gener
resist
expuls
pocket
factor
use
skeleton
pleconaril
relat
molecul
novel
class
imidazolidinon
synthes
signific
activ
ic
rang
mm
virus
encod
one
sever
proteas
play
crucial
role
viral
life
cycl
viral
proteas
carri
proteolysi
polyprotein
precursor
releas
function
viral
protein
allow
function
correctli
individu
replicationtranscript
matur
viral
proteas
also
effect
protect
viral
protein
modul
host
cell
pathway
includ
ubiquitin
isgyl
contrast
divers
viral
proteas
function
structur
catalyt
activ
site
viral
proteas
gener
stringent
substrat
specif
protein
cleavag
synthet
substrat
peptid
design
accord
natur
substrat
individu
viral
proteas
usual
gener
highaffin
bind
thu
provid
potent
candid
drug
discoveri
one
great
success
proteas
inhibitor
pi
ten
pi
current
approv
treat
infect
amprenavir
apv
atazanavir
atz
darunavir
fosamprenavir
lexiva
indinavir
idv
lopinavir
lpv
nelfinavir
nfv
ritonavir
rtv
saquinavir
sqv
tipranavir
tpv
pi
share
rel
similar
chemic
structur
deriv
natur
peptid
substrat
therefor
crossresist
pi
occur
activ
site
proteas
result
pi
commonli
use
combin
antihiv
drug
avoid
drug
resist
pharmaceut
disadvantag
overcom
pi
becom
potent
type
antivir
drug
current
progress
gener
antivir
pi
systemat
review
elsewher
almost
virus
encod
polymeras
central
step
replic
transcript
thu
polymeras
becom
attract
suitabl
target
antivir
develop
base
function
structur
viral
polymeras
two
major
type
polymeras
inhibitor
nucleosid
nucleotid
substrat
analog
ii
alloster
inhibitor
nucleosid
nucleotid
analog
play
domin
role
antivir
drug
target
viral
polymeras
nucleosid
analog
first
triphosph
host
cell
produc
activ
inhibitor
act
inhibitor
compet
natur
nucleosid
triphosph
termin
grow
viral
nucleic
acid
disadvantag
nucleosid
analog
initi
phosphoryl
step
product
monophosphoryl
form
requir
activ
triphosph
may
correctli
occur
host
cell
therefor
monophosph
nucleotid
analog
develop
polymeras
inhibitor
avoid
problem
date
approv
antivir
drug
antihiv
therapi
util
mechan
includ
zidovudin
azt
other
strategi
also
success
use
develop
antivir
wide
rang
virus
includ
cytomegaloviru
cmv
herp
simplex
viru
hsv
herpesvirida
famili
hepat
b
viru
hbv
hepadnavirida
famili
hcv
cours
polymeras
cycl
rel
orient
polymeras
domain
undergo
slight
shift
shift
caus
conform
chang
specif
site
alloster
site
viral
polymeras
therefor
compound
bind
alloster
site
could
conceiv
block
structur
movement
polymeras
domain
thu
inhibit
function
viral
polymeras
antivir
inhibitor
work
mechan
known
alloster
inhibitor
alloster
inhibitor
hiv
revers
transcriptas
rt
also
known
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nnrti
hydrophob
bind
site
hiv
rt
first
identifi
screen
compound
librari
rt
combin
structur
biolog
analysi
bind
nnrti
rt
prevent
flexibl
movement
rt
requir
elong
nucleic
acid
date
five
nnrti
nevirapin
delavirdin
efavirenz
etravirin
rilpivirin
approv
fda
clinic
use
treat
infect
furthermor
develop
nnrti
viral
polymeras
hcv
ongo
polymeras
like
suitabl
site
alloster
inhibitor
integras
enzym
help
retroviru
facilit
incorpor
provir
dna
host
cell
genom
catalyz
vital
function
viral
replic
inhibitor
integras
repres
newest
class
figur
raltegravir
integras
strand
transfer
inhibitor
insti
first
gener
drug
class
approv
potent
welltoler
antivir
agent
dolutegravir
advanc
second
gener
insti
possess
good
toler
oncedaili
dose
need
pharmacolog
enhanc
rel
littl
crossresist
raltegravir
anoth
insti
elvitegravir
recent
approv
treatment
hiv
infect
part
fix
dose
combin
known
stribild
furthermor
inhibitor
len
epitheliumderiv
growth
factor
ledgf
bind
site
integras
ledgin
also
develop
still
earli
stage
drug
contribut
new
benefit
class
extend
treatment
option
patient
infect
terminu
genom
rna
subset
rna
virus
requir
cap
structur
directli
taken
mrna
host
cell
influenza
viru
synthes
viral
enzym
flaviviru
coronaviru
latter
case
cap
structur
gener
seri
enzym
attach
first
nucleotid
genom
rna
via
triphosph
linker
exampl
genom
flaviviru
cap
type
cap
structur
gpppam
methyl
posit
guanin
g
oh
ribos
first
nucleotid
genom
rna
three
enzymat
step
requir
form
cap
structur
includ
rna
triphosphatas
guanylyl
transferas
gtase
methyltransferas
mtase
provid
n
terminu
protein
base
structur
mtase
complex
differ
substrat
three
key
ligandbind
site
identifi
figur
bind
site
sadenosyl
methionin
sam
act
methyl
donor
locat
core
domain
mtase
wherea
bind
site
receiv
gtp
molecul
guanin
moieti
rna
cap
form
core
domain
ntermin
extens
moreov
anoth
site
bind
rna
sam
gtp
pocket
site
known
second
lower
affin
bind
site
form
core
domain
channel
two
helic
ntermin
extens
site
crucial
mtase
activ
viru
replic
valid
site
design
dvta
figur
ribavirin
first
shown
inhibit
bind
rna
cap
dengu
viru
denv
mtase
competit
bind
gtprna
cap
pocket
structurebas
drug
design
aurintricarboxyl
acid
found
inhibit
activ
denv
mtase
ic
mm
bind
lower
affin
site
anoth
inhibitor
sinefungin
analog
sam
methyl
sulfur
sam
replac
carbon
amin
inhibit
flaviviru
activ
ic
low
mm
recent
compound
discov
use
highthroughput
screen
ht
method
vitro
inhibitor
guanylyltransferas
activ
denv
mtase
thu
denv
replic
howev
inhibitor
must
use
high
concentr
outcompet
highaffin
endogen
ligand
necessari
solv
problem
mechan
clinic
exploit
virus
util
viral
helicas
separ
one
strand
dna
rna
complementari
strand
process
driven
adenosin
triphosph
atp
hydrolysi
wide
studi
viral
helicas
flavivir
helicas
helicas
domain
nonstructur
protein
encod
hcv
sarscov
protein
simian
viru
polyomavirida
famili
tag
protein
hpv
protein
also
known
encod
helicas
replic
inhibitor
helicasecatalyz
atp
hydrolysi
straightforward
class
sever
nucleotid
nucleobas
analog
discov
target
mechan
biphenyl
triphenylmethan
studi
inhibitor
tag
hpv
hcv
helicas
biphenyl
biphenysulfonacet
acid
found
inhibit
hpv
growth
inhibitor
hpv
atp
hydrolysi
ic
valu
mm
compound
similar
triclocarban
bisphenol
bpa
found
inhibit
helicas
activ
tag
base
complex
structur
hcv
helicas
domain
solubl
blue
ht
pdb
code
triphenylmethan
potent
triphenylmethan
aurintricarboxyl
acid
ata
develop
inhibit
helicas
activ
hcv
nucleic
acid
bind
site
helicas
also
promis
site
discoveri
antivir
compound
directli
inhibit
helicasecatalyz
unwind
exampl
mani
dnabind
pharmacophor
anthracyclin
acridon
tropolon
amidinoanthracyclin
optim
hcv
helicas
inhibitor
although
numer
effort
launch
find
antivir
target
viral
helicas
littl
progress
made
push
clinic
usag
project
met
great
challeng
cytotox
bioavail
pharmacokinet
properti
replic
transcript
complex
blocker
follow
viral
entri
viral
protein
togeth
number
host
cell
factor
assembl
viral
replic
transcript
complex
rtc
respons
product
viral
genom
nucleic
acid
therefor
reagent
effici
block
format
viral
rtc
could
conceiv
inhibit
viral
prolifer
exampl
hcv
enter
host
cell
genom
hcv
work
mrna
produc
viral
protein
form
rtc
host
factor
account
viral
replic
transcript
membraneassoci
nonstructur
phosphoprotein
believ
enzymat
activ
play
critic
role
regul
format
hcv
rtc
gao
et
al
identifi
potent
hcv
inhibitor
target
produc
side
effect
phase
clinic
studi
although
exact
mechan
exert
effect
yet
defin
resist
profil
reveal
inhibitor
sensit
map
n
terminu
domain
inhibitor
shown
block
hyperphosphoryl
believ
play
essenti
role
viral
life
cycl
work
first
time
prove
concept
small
molecul
target
nontradit
viral
protein
without
known
enzymat
activ
also
profound
antivir
effect
consider
promis
treatment
hcv
infect
replic
picornavirus
polymeras
also
name
pol
also
name
vpg
proteas
also
name
pro
particip
format
viral
rtc
togeth
host
polyabind
protein
polycbind
protein
unlik
mani
virus
replic
picornaviru
genom
initi
end
genom
coval
link
vpg
socal
vpg
uridylyl
process
although
vpgbind
site
vari
picornavirus
bind
vpg
pol
known
critic
vpg
uridylyl
viru
replic
recent
studi
demonstr
ten
amino
acid
peptid
vpg
effect
inhibit
vpg
uridylyl
process
ec
low
nm
z
lou
et
al
unpublish
result
shed
light
discov
futur
indvta
throughout
life
cycl
neg
sens
singlestrand
rna
ssrna
viru
genom
length
rna
encapsid
viral
encod
nucleoprotein
np
instead
nake
rna
associ
rdrp
polymeras
complex
form
stabl
ribonucleoprotein
rnp
complex
respons
viru
replic
transcript
assembl
process
np
protect
rna
exogen
nucleas
innat
immun
system
host
cell
base
crystallograph
achiev
regard
ssrna
viru
rnp
complex
past
year
great
progress
made
new
put
antivir
strategi
kao
et
al
first
identifi
compound
nucleozin
trigger
aggreg
inhibit
nuclear
accumul
np
compound
inhibit
replic
influenza
viru
nanomolar
median
effect
concentr
ec
parallel
effort
gerritz
et
al
discov
seri
influenza
replic
inhibitor
show
interfer
npdepend
process
via
format
higher
order
np
trend
pharmacolog
scienc
februari
vol
oligom
ec
nm
notabl
structur
np
complex
repres
compound
class
inhibitor
reveal
two
molecul
inhibitor
antiparallel
orient
lock
two
adjac
np
protom
unexpect
quaternari
complex
explain
viral
inhibit
via
ligandinduc
format
stabl
np
oligom
addit
inhibit
np
disrupt
polymeras
complex
influenza
viru
propos
antivir
strategi
base
complex
structur
pa
ctermin
domain
pa
c
first
amino
acid
subset
modif
ntermin
peptid
shown
diminish
bind
affin
pa
inhibit
polymeras
activ
attenu
replic
influenza
viru
moreov
structur
sftsv
np
complex
suramin
antivir
inhibitor
reveal
blocker
bind
rnabind
caviti
attenu
sftsv
replic
indic
target
rnp
format
may
new
therapeut
antivir
approach
polymeras
complex
np
show
signific
conserv
differ
influenza
virus
result
demonstr
target
format
viral
rnp
valid
approach
develop
small
molecul
therapi
seriou
antivir
resist
current
avail
drug
adamantan
neuraminidas
inhibitor
key
interact
viral
protein
andor
host
factor
play
essenti
role
viru
entri
replic
matur
interest
exampl
interact
hpv
protein
help
helicas
tether
hpv
origin
replic
interact
therefor
use
guid
develop
antivir
treat
hpv
infect
disrupt
hpv
interact
first
facilit
potent
inhibitor
inhibitor
effect
diminish
interact
hpv
thu
inhibit
hpv
prolifer
ec
nm
although
indvta
discov
antivir
therapi
mechan
work
still
requir
investig
conclud
possibl
indvta
may
addit
function
may
major
function
categori
antivir
refin
accord
knowledg
virus
util
mani
host
factor
effici
prolifer
correct
function
host
factor
crucial
viru
replic
therefor
compound
regul
function
host
factor
introduc
antivir
agent
next
discuss
two
host
factor
involv
broad
spectrum
viru
infect
apart
acquir
immun
respons
host
cell
mount
number
defens
innat
immun
respons
viru
infect
interferon
ifn
one
crucial
molecul
innat
immun
respons
act
primari
switch
initi
antivir
immun
vertebr
upon
infect
viru
host
cell
produc
secret
type
mainli
ifna
ifnb
type
iii
ifnl
ifn
secret
ifn
interact
membraneanchor
ifn
receptor
ifnar
mainli
subsequ
stimul
upregul
express
hundr
ifnstimul
gene
isg
inhibit
replic
virus
among
isg
ifninduc
transmembran
ifitm
protein
restrict
entri
influenza
viru
west
nile
viru
wnv
denv
addit
mx
myxoviru
resist
gtpase
inhibit
correct
function
viral
nucleocapsid
polymeras
influenza
viru
due
signific
ifn
host
cell
restrict
viral
infect
ifn
use
certain
instanc
primari
antivir
therapi
particularli
absenc
effect
antivir
vaccin
strategi
use
ifn
antivir
therapi
first
develop
treat
hbv
infect
subsequ
appli
treat
hcv
combin
ribavirin
ifnb
ifng
also
evalu
use
antihcv
treatment
improv
therapeut
efficaci
ifna
therapi
sever
option
investig
clinic
benefit
observ
pilot
studi
ofloxacin
immunomodulatori
peptid
particular
pegmodifi
ifna
combin
ribavirin
standard
treatment
hcv
infect
cyclophilin
cyp
key
cellular
factor
function
numer
cellular
process
includ
transcript
regul
immun
respons
protein
secret
mitochondri
function
cyclophilin
cypa
key
member
cyp
famili
first
identifi
mediat
immunosuppress
function
cyclosporin
csa
format
csacypa
complex
complex
bind
inhibit
function
protein
phosphatas
calcineurin
normal
function
dephosphoryl
nfat
transcript
factor
import
cell
activ
cypa
also
known
play
critic
role
prolifer
virus
includ
influenza
viru
hcv
vesicular
stomat
viru
vsv
vaccinia
viru
sarscov
rotaviru
rv
hpv
interact
viral
protein
facilit
ifnb
product
cypa
first
reveal
incorpor
virion
interact
capsid
protein
ca
interact
newli
synthes
ca
cypa
requir
induc
dendrit
cell
matur
cypa
also
interact
protein
vpr
regul
hiv
infect
sever
line
evid
indic
cypa
cyclophilin
b
cypb
function
replic
hcv
either
increas
affin
hcv
polymeras
viral
rna
enhanc
hcv
replic
bind
hcv
protein
aid
viral
replic
discoveri
cypa
inhibitor
antivir
agent
start
immunosuppress
drug
csa
inhibit
hcv
hiv
basi
result
cypa
antagonist
often
deriv
review
trend
pharmacolog
scienc
februari
vol
csa
develop
includ
alisporivir
compound
lack
immunosuppress
effect
retain
highaffin
cypa
bind
show
good
antivir
effect
hiv
hcv
infect
coreceptor
antagonist
coreceptor
antagonist
block
interact
andor
also
introduc
antihiv
effort
success
instanc
antagonist
potent
inhibit
replic
good
pharmaceut
properti
includ
aplaviroc
maraviroc
clinic
use
antihiv
drug
coreceptor
antagonist
vicriviroc
cenicriviroc
success
advanc
phase
iiiii
clinic
trial
approv
clinic
usag
past
year
howev
precis
mechan
coreceptor
antagonist
still
clear
recent
crystal
structur
report
two
structur
provid
atom
inform
ligandbind
pocket
site
coreceptor
oligomer
structur
studi
complex
antagonist
promot
investig
inhibitori
mechan
inhibitor
help
us
increas
antihiv
efficaci
present
divers
antivir
drug
clinic
approv
later
stage
clinic
trial
base
conserv
mechan
describ
review
particular
target
viral
polymeras
proteas
howev
major
drugresist
infect
case
report
usag
antivir
base
strategi
requir
new
antivir
drug
treat
chronic
infecti
diseas
emerg
effici
new
virus
serv
catalyst
research
find
addit
target
mechan
antivir
develop
novel
strategi
introduc
antivir
research
includ
inhibitor
viral
mtase
helicas
blockag
viral
rtc
format
eg
nucleozin
influenza
host
factor
antagonist
agonist
howev
proteas
polymeras
inhibitor
still
occupi
domin
place
among
antivir
still
precis
knowledg
mechan
underli
altern
strategi
requir
investig
mechan
strategi
wide
use
antivir
develop
particular
target
drugresist
viral
infect
opinion
proteas
polymeras
inhibitor
still
first
probabl
major
choic
develop
therapi
emerg
novel
virus
addit
must
consid
anoth
import
aspect
antivir
develop
virus
current
avail
drug
effect
elimin
viru
host
genet
compon
left
behind
thu
host
still
suffer
infect
viru
integr
genet
host
cell
exampl
treatment
combin
inf
adefovir
antivir
effect
complet
reduc
hbv
titer
human
liver
howev
coval
close
circular
dna
cccdna
remov
still
exist
nuclei
infect
liver
cell
continu
coordin
express
hbv
antigen
therefor
new
mechan
strategi
complet
remov
viral
compon
integr
host
cell
well
kill
viru
requir
futur
antivir
develop
